Conferences - Results from #220

ASCO GU 2025: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib in Combination with Androgen Receptor Pathway Inhibitors in Patients with mHSPC with and Without Homologous Recombination Repair Mutation February 18, 2025

ASCO GU 2025: Outcomes for 177Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with mCRPC February 18, 2025

ASCO GU 2025: Prospective Real World Data Evaluation of Clinical Outcomes in mHSPC Patients Treated as Part of Triplet Therapy with Darolutamide: UK Multicenter RECOmMEnD Study February 17, 2025

ASCO GU 2025: Prostate Cancer Risk Groups by PSMA-PET PROMISE: Results from an International Multi-Center Registry Study February 17, 2025

ASCO GU 2025: PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing February 17, 2025

ASCO GU 2025: PSA Response and Survival Based on Metastatic Site in Patients with mCRPC Treated with 177Lu-PSMA-617 February 17, 2025

ASCO GU 2025: Re-Treatment of mCRPC Patients with Radium-223 Therapy in Daily Practice February 16, 2025

ASCO GU 2025: Secondary Outcomes by Prior Definitive Treatment in Patients with High-Risk Biochemically Recurrent Prostate Cancer Treated with Enzalutamide Monotherapy: EMBARK Post Hoc Analysis February 16, 2025

ASCO GU 2025: Seeing Is Believing: Radiographic Criteria to Assess Response February 16, 2025

ASCO GU 2025: Real-World Outcomes Among Patients with mCRPC Receiving Guideline-Recommended Therapies After Treatment with 177Lu-PSMA-617: A Real-World Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis February 16, 2025

ASCO GU 2025: Treatment Patterns in Prostate Cancer Patients Who Received Darolutamide in the ARAMIS Trial in Spain: PARASEC Study February 16, 2025

ASCO GU 2025: Using AI to Identify Optimal Clinical, Genomic, and Radiographic Prognostic Features and Novel Risk Classifiers Compared to Routinely Available Risk Classifiers February 16, 2025

ASCO GU 2025: Utility of Post-Treatment SPECT/CT for Identifying Disease Progression in Patients with mCRPC Treated with 177Lu-PSMA-617 February 16, 2025

ASCO GU 2025: Evaluation of Circulating Kidney Injury Marker-1 (KIM-1) as a Prognostic and Predictive Biomarker in Advanced Renal Cell Carcinoma: Post-Hoc Analysis of CheckMate 214 February 16, 2025

ASCO GU 2025: Final Overall Survival and New ctDNA Analysis in MET-Driven Advanced Papillary Renal Cancer (CALYPSO) February 16, 2025

ASCO GU 2025: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma: Final Follow-up Results from the CheckMate 9ER Trial February 16, 2025

ASCO GU 2025: Casdatifan Monotherapy in Patients with Previously Treated Clear Cell Renal Cell Carcinoma (ccRCC): Safety, Efficacy and Subgroup Analysis Across Multiple Doses from ARC-20, a Phase 1 Open-Label Study February 16, 2025

ASCO GU 2025: EPIC-A: Phase II Trial of Cemiplimab plus Standard of Care Chemotherapy Followed by Maintenance Cemiplimab in Locally Advanced or Metastatic Penile Carcinoma February 16, 2025

ASCO GU 2025: ResQ132A: Phase 2 Trial of Intravesical Gemcitabine Plus N-803 Versus Intravesical N-803 and BCG for Intermediate-Risk NMIBC February 16, 2025

ASCO GU 2025: Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (EA8211-SOAR) February 16, 2025

Page 12 of 616